Lost Opportunity: What Happened to Novel Cannabis Research?

The Canadian cannabis industry has seen multiple levels of hype. Where did it leave the business of novel cannabis research?

Cannabis legalization in Canada brought the promise of global business opportunities, but it also led to missed potential in research on the medical side.

Even before the days of adult-use legalization in Canada, the market had seen a barrage-like cycle of ups and downs, creating uncertainty about where to find solid investment opportunities.

These bumps are likely to continue due to the volatile nature of the industry, but does that mean medical cannabis research will get a chance to shine? Here’s how experts think the situation will play out.

Recreational cannabis clouding research opportunities

Since cannabis legalization took place in Canada back in 2018, its sibling market south of the border has matured from a risky, small-scale and unapproachable opportunity to the unquestionable number one choice to go with for any kind of cannabis investment.

But while the US cannabis space has become appealing to investors, a key piece of the puzzle is still missing. One of the main desires for the industry is the complete opening of the recreational market.

Notably, cannabis researcher New Frontier Data recently indicated that by 2025, legal cannabis sales will amount to US$43 billion. The data shows that so far in 2021, there’s been just over US$6 billion invested into the cannabis industry.

It’s also hoped that banking and other financial tools — such as senior listings for US-based companies — will become available. From there, cannabis plays may be able to attract larger investors.

However, in a recent interview with BNN Bloomberg, Bruce Linton, an active figure in the industry and someone who helped shape much of the current landscape for cannabis investments, expressed disappointment surrounding the sole focus he perceives for recreational options.

When asked what the US can learn from Canada, he explained that there is not nearly enough attention being put towards science and research innovation in the cannabis industry.

“(Canada) for sure did a good job in getting out of the gates on recreational … but I don’t hear anything about science anymore and I certainly don’t hear enough about the medical program,” Linton said.

The former Canopy Growth (NASDAQ:CGC,TSX:WEED) executive highlighted an avenue of the business that he thinks needs to be addressed urgently.

“I would say maybe our misstep in Canada has been that we’ve been so busy working on the party we forgot about the 300 or 400, 500 million people under governance of a medical program, so there may be a bit of a lost opportunity there,” he added.

Although a move toward full legalization is heavily anticipated in the US, experts have told the Investing News Network (INN) many times in the past that investors need to be aware of the glacial pace of politics, particularly in the US. A quick resolution will not likely be at hand here.

Squandered opportunity highlights need to reevaluate

Linton isn’t the only cannabis expert who believes the exploration of cannabinoid drugs has so far represented some squandered potential for Canadian operators.

However, in some ways it’s understandable that few companies have gone this route. “It is a lost opportunity,” Nawan Butt, a portfolio manager with Purpose Investments, said. “But it also requires a lot of capital. I’d say the problem with the Canadian industry has been just inefficient allocation of capital.”

Butt told INN he no longer sees Canadian licensed producers, or for that matter US-based multi-state operators, as the companies expected to push the boundaries for cannabis-based drugs.

“We don’t think that’s a focus for any of the larger companies within Canada or the US, they’re very much focused on … the lowest-hanging fruit, which is federal reform in the US,” the expert said. Butt did clarify that this low-hanging fruit represents an US$80 billion opportunity that most can’t afford to dismiss.

Still, the lessons learned from Canadian legalization have left some companies behind. “This is a more nuanced industry, Canada has a head start on the world in something that can be much larger than just the Canadian market and a lot of the licensed producers have squandered that opportunity,” he told INN.

Investor takeaway

There are many unknowns ahead for investors in the cannabis industry — there will undoubtedly be new heights and similarly potential pitfalls moving forward.

When it comes to medical cannabis and the business of advanced research and drug development, time will tell about the potential benefits of betting on this aspect of the market.

“The fact that everyone is just so consumed by this idea that only (recreational) cannabis matters, I think, is a fallacy,” Aurora Cannabis (NASDAQ:ACB,TSX:ACB) CEO Miguel Martin told Business Insider recently.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Featured
Cronos Group Inc. is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 Management Cease Trade Orders . On November 9, 2021, the Company announced that it applied for a management cease trade order with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Quarterly Report on Form ...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 Management Cease Trade Orders (" NP 12-203 ").

On November 9, 2021, the Company announced that it applied for a management cease trade order (" MCTO ") with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the " Form 10-Q ") with the U.S. Securities and Exchange Commission (the " SEC "), together with its corresponding quarterly filings in Canada (collectively, the " Required Filings "), by the applicable filing deadlines (the " Original Announcement "). The MCTO was issued on November 16, 2021 and restricts all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company until two full business days following the filing of the Required Filings and the MCTO has been revoked. The MCTO does not affect the ability of other shareholders of the Company to trade their securities.

read more Show less
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. for violations of the securities lawsThe investigation focuses on whether the Company issued false andor misleading statements andor failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or "the Company") (NASDAQ:CRON) for violations of the securities laws

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021" and that "the Company's financial statements for this period should therefore no longer be relied upon." Based on this news, shares of Cronos fell by nearly 16%.

read more Show less
Florida's leading medical cannabis company to open its 110 th dispensary in the state, invites Tampa community to join ribbon cutting and grand opening celebration Trulieve Cannabis Corp. a leading and top-performing cannabis company in the United States today announced the opening of its newest dispensary located on North Dale Mabry Highway in Tampa, Florida . Trulieve will host a ribbon cutting and begin serving ...

Florida's leading medical cannabis company to open its 110 th dispensary in the state, invites Tampa community to join ribbon cutting and grand opening celebration

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of its newest dispensary located on North Dale Mabry Highway in Tampa, Florida . Trulieve will host a ribbon cutting and begin serving patients at this location at 9:00 am on Thursday, December 2 and will continue the celebration with all-day festivities and deals. The new location is Trulieve's 110 th dispensary in Florida and its 157 th nationwide.

read more Show less

MARKETS

Markets
TSX20633.27-128.76
TSXV897.13-13.09
DOW34580.08-59.71
S&P 5004538.43-38.67
NASD15085.47-295.85
ASX7241.20+16.00

COMMODITIES

Commodities
Gold1783.44+1.06
Silver22.54+0.03
Copper4.27-0.03
Palladium1816.01+10.01
Platinum936.31+3.31
Oil66.22-0.28
Heating Oil2.10-0.01
Natural Gas4.09+0.04